Independently acquired biallelic JAK2 mutations are present in a minority of patients with essential thrombocythemia

Blood

Volumn 116, Issue 6, 2010, Pages 1013-1014

  Beer, Philip A ^a,b   Ortmann, Christina A ^a,b   Campbell, Peter J ^b,c   Green, Anthony R ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956538421     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-284356     Document Type: Letter

References (6)

1. Lambert JR, Everington T, Linch DC, Gale RE. In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm. Blood. 2009;114(14):3018-3023.
2. Olcaydu D, Harutyunyan A, Jager R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-454.
3. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-449.
4. Harrison CN, Bareford D, Butt N, et al. BCSH guidelines for investigation and management of patients presenting with a thrombocytosis. Br J Haematol. 2010;149(3):352-375.
5. Kanagawa T. Bias and artifacts in multitemplate polymerase chain reactions (PCR). J Biosci Bioeng. 2003;96(4):317-323. (Pubitemid 37500201)
6. Speksnijder AG, Kowalchuk GA, De Jong S, Kline E, Stephen JR, Laanbroek HJ. Microvariation artifacts introduced by PCR and cloning of closely related 16S rRNA gene sequences. Appl Environ Microbiol. 2001;67(1):469-472. (Pubitemid 32044454)